6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

---

For the month of March 2026

Commission File Number: 001-40552

NYXOAH SA

(Translation of registrant’s name into English)

RueEdouard Belin 12, 1435 Mont-Saint-Guibert, Belgium

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Nyxoah SA

On March 19, 2026, Nyxoah SA (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

Additionally, on February 25, 2026, February 27, 2026 and March 13, 2026, the Company issued releases, copies of which are attached hereto as exhibits 99.2, 99.3 and 99.4.

Theinformation in the attached Exhibit 99.1, 99.2, 99.3 and 99.4 is being furnished and shall not be deemed “filed” for the purposesof Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilitiesof that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933,as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in sucha filing.

Exhibits

99.1	Press Release, dated<br> March 19, 2026
99.2	Press Release, dated<br> February 25, 2026
99.3	Press Release, dated<br> February 27, 2026
99.4	Press Release, dated<br> March 13, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NYXOAH SA
Date: March 19, 2026	By:	/s/ John Landry
	Name:	John Landry
	Title:	Chief Financial Officer

Exhibit 99.1

REGULATEDINFORMATION

NyxoahReports Fourth Quarter and Full Year 2025 Financial and Operating Results

U.S.Commercialization Off to a Strong Start in First Full Quarter of Sales

FoundationEstablished to Drive Significant Growth in 2026

Mont-Saint-Guibert,Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025.

RecentFinancial and Operating Highlights

·	Fourth<br> quarter gross revenue of €6.3 million, resulting in net revenue of €5.6 million,<br> which represents 347% year-over-year growth, driven by the first full quarter of US commercialization
·	Full<br> year gross revenue of €11.0 million, resulting in net revenue of €10.0 million,<br> which represents 122% year-over-year growth
---	---
·	Fourth<br> quarter gross margin of approximately 64%
---	---
·	Cash,<br> cash equivalents and financial assets of €48.0 million at December 31, 2025
---	---
·	145<br> surgeons trained and 57 accounts activated in the U.S. since commercial launch in August 2025
---	---
·	Genio<br> system consistently reimbursed by both commercial payors and Medicare to date
---	---
·	Expanding<br> manufacturing footprint to support global growth
---	---

“The fourth quarter marked our first full quarter of U.S. commercialization, and we are very pleased with the strong momentum we generated which led to us exceeding our revenue expectations for the quarter,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “The feedback from surgeons and their patients has been positive and these procedures have been consistently reimbursed by major commercial payors and Medicare to date. We are excited about the opportunity in front of us and feel confident we will deliver significant growth going forward.”

1

U.S.Commercial Launch

The fourth quarter represented the first full quarter of commercial activity in the United States following FDA approval of the Genio® system in August 2025. The Company is executing its focused two-pronged launch strategy targeting high-volume hypoglossal nerve stimulation implanting centers while educating referral networks with sleep physicians managing moderate to severe OSA patients.

As of December 31, 2025:

·	145<br> surgeons had been trained on the Genio system
·	57<br> U.S. accounts had been activated
---	---
·	Genio<br> has been consistently reimbursed by many large commercial payors and Medicare to date
---	---

2

CONSOLIDATEDSTATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)

(inthousands EUR)

	For year ended <br><br>December 31						For the three months<br><br> ended December 31
	2025			2024			2025			2024
Revenue		10 020			4 521			5 644			1 263
Cost of goods sold		(3<br>694	)		(1<br>552	)		(2 019	)		(335	)
Gross profit	€	6,326		€	2,969		€	3 625		€	928
Research and Development Expense		(42<br>824	)		(34,325	)		(10,865	)		(11,752	)
Selling, General and Administrative Expense		(48,261	)		(28,461	)		(12,496	)		(8,065	)
Other income		1,274			1,008			1,108			578
Operating loss for the period	€	(83,485	)	€	(58,809	)	€	(18,628	)	€	(18,311	)
Financial income		5 928			7 447			(633	)		2 832
Financial expense		(11 519	)		(5<br>070	)		(3<br>357	)		(410	)
Loss for the period before taxes	€	(89 076	)	€	(56 432	)	€	(22618	)	€	(15 069	)
Income taxes		(1 009	)		(2<br>804	)		(895	)		(2 080	)
Loss for the period	€	(90085	)	€	(59236	)	€	(23 513	)	€	(17 149	)
Loss attributable to equity holders	€	(90085	)	€	(59236	)	€	(23 513	)	€	(17 149	)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Remeasurements of post-employment benefit obligations, net of tax		(18	)		11			(18	)		(11	)
Currency translation differences		228			766			31			(987	)
Total comprehensive loss for the year, net of tax		210			777			13			(976	)
Loss attributable to equity holders	€	(89,875	)	€	(58,459	)	€	(23,500	)	€	(16,151	)
Basic Loss Per Share (in EUR)	€	(2.364	)	€	(1.809	)	€	(0.586	)	€	(0.463	)
Diluted Loss Per Share (in EUR)	€	(2.364	)	€	(1.809	)	€	(0.586	)	€	(0.463	)

3

CONSOLIDATEDSTATEMENT OF FINANCIAL POSITION (unaudited)

(inthousands EUR)

	As at December 31
	2025			2024
ASSETS
Non-current assets
Property, plant and equipment		4,052			4,753
Intangible assets		50,108			50,381
Right of use assets		1,293			3,496
Deferred tax asset		87			76
Other long-term receivables		1,718			1,617
	€	57,258		€	60,323
Current assets
Inventory		4,660			4,716
Trade receivables		5,254			3,382
Contract assets		261			-
Other receivables		2,209			2,774
Other current assets		828			1,656
Financial assets		18,000			51,369
Cash and cash equivalents		30,001			34,186
	€	61,213		€	98,083
Total assets	€	118,471		€	158,406
EQUITY AND LIABILITIES
Share capital and reserves
Share capital		6,505			6,430
Share premium		335,134			314,345
Share-based payment reserve		12,395			9,300
Other comprehensive income		1,124			914
Retained loss		(306<br>029	)		(217,735	)
Total equity attributable to shareholders	€	49,129		€	113,254
LIABILITIES
Non-current liabilities
Financial debt		17,670			18,725
Lease liability		637			2,562
Provisions		1,396			1,000
Deferred tax liability		-			19
Contract liability		681			472
Other liability		-			845
	€	20,384		€	23,623
Current liabilities
Financial debt		22,990			248
Lease liability		779			1,118
Trade payables		13,727			9,505
Current tax liability		3,939			4,317
Contract liability		894			117
Other liability		6,629			6,224
	€	48,958		€	21,529
Total liabilities	€	69,342		€	45,152
Total equity and liabilities	€	118,471		€	158,406

4

Revenue

Gross revenue for the fourth quarter of 2025 was €6.3 million before €0.7 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €5.6 million compared to €1.3 million in the fourth quarter of 2024.

For the full year 2025, gross revenue was €11.0 million before €1.0 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €10.0 million compared to €4.5 million in 2024. The increase in net revenue was primarily due to the launch of U.S. commercialization activities beginning in August 2025, post PMA approval.

Costof Goods Sold

Cost of goods sold was €2.0 million for the three months ended December 31, 2025, resulting in gross profit of €3.6 million and a gross margin of approximately 64%, compared to cost of goods sold of €0.3 million and gross margin of 73% in the fourth quarter of 2024.

For the full year ended December 31, 2025, cost of goods sold was €3.7 million, resulting in gross profit of €6.3 million and a gross margin of approximately 63%, compared to cost of goods sold of €1.6 million and gross margin of 66% in 2024. The increase in cost of goods sold was due to a higher volume of Genio systems sold in 2025 while gross margin decreased slightly on a year over year basis due to initial ramp-up operational activities in advance of the Company’s U.S. commercial launch.

Researchand Development

Research and development expenses were €10.9 million for the fourth quarter of 2025, compared to €11.8 million for the fourth quarter of 2024.

For the full year ended December 31, 2025, research and development expenses were €42.8 million, compared to €34.3 million in 2024. The increase in research and development expenses was primarily driven by continued clinical expansion initiatives and ongoing product development activities.

Selling,General and Administrative

Selling, general and administrative expenses were €12.5 million for the fourth quarter of 2025, compared to €8.1 million for the fourth quarter of 2024.

For the full year ended December 31, 2025, selling, general and administrative expenses were €48.3 million, compared to €28.5 million in 2024. The increase was primarily driven by the build-out of the Company’s U.S. commercial organization, including sales, marketing, and market access functions.

OperatingLoss

Total operating loss for the fourth quarter of 2025 was €18.6 million, compared to €18.3 million in the fourth quarter of 2024.

5

For the full year ended December 31, 2025, total operating loss was €83.5 million, compared to €58.8 million in 2024. The increase reflects the planned acceleration of U.S. commercialization investments, continued clinical expansion initiatives and ongoing product development activities.

CashPosition

Cash, cash equivalents and financial assets amounted to €48.0 million at December 31, 2025.

RevenueGuidance

·	We<br> expect U.S. net revenue for the first quarter of 2026 to grow by approximately 25% over the<br> fourth quarter of 2025 and expect net revenue for the second quarter of 2026 to grow by approximately<br> 25% over the first quarter of 2026.
·	International<br> revenue is expected to follow a typical seasonal pattern.
---	---

AnnualReport 2025

Nyxoah is currently finalizing the financial statements for the year ended December 31, 2025. The Company’s independent auditor has confirmed that their audit procedures, which have been substantially completed, have not revealed any material adjustments which would have to be made to the accounting information included in this press release. The complete consolidated financial statements for the year ended December 31, 2025 as well as the complete audit report related to the audit of the consolidated financial statements will be included in the 2025 Annual Report which the Company aims to publish on or around March 26, 2026. When published, the Nyxoah Annual Report for the financial year 2025 will be available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conferencecall and webcast presentation

Company management will host a conference call to discuss financial results on Thursday, March 19, 2026, beginning at 9:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 and FY 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah's Q4 and FY 2025 Earnings Call Q&A Link. required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

AboutNyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

6

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-lookingstatements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue results and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and any subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

7

Contacts:

Nyxoah

John Landry, CFO

IR@nyxoah.com

Rémi Renard

Head of Investor Relations & Corporate Communication

IR@nyxoah.com

8

Exhibit 99.2

Information on the total number of voting rights and shares

February 25, 2026

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), February 25,2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026.

·	Share capital: EUR 6,511,048.19
·	Total number of securities carrying voting rights: 43,662,403<br>(all ordinary shares)
·	Total number of voting rights (= denominator): 43,662,403 (all<br>relating to ordinary shares)
·	Number of rights to subscribe to securities carrying voting<br>rights not yet issued: 3,416,319 (all granted subscription rights; this number excludes 462,677 subscription rights that were issued<br>but not yet granted)
·	Total number of convertible bonds: 225 convertible bonds with<br>a nominal value of EUR 91,500 per bond
·	Total number of voting rights that can be obtained in case of<br>conversion of all 225 convertible bonds at the current conversion price of EUR 5.00 per share: 4,117,500

*

* *

Contact:

---

Nyxoah

John Landry, CFO

IR@nyxoah.com

Attachment

· 2026 02 25 - Press release - Number of shares (ENG)

Exhibit 99.3

Publication relating to transparency notifications

February 27, 2026

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), February 27,2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

Robert Taub / BMI Estate

On February 26, 2026, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate, following the passive crossing of a threshold. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 9.99% of the total number of voting rights on February 20,

2026 (43,662,403).

The notification dated February 26, 2026 contains the following information:

·	Reason for the notification: passive crossing of a threshold
·	Notification by: a parent undertaking or a controlling person
·	Persons subject to the notification requirement:
·	Robert Taub
---	---
·	BMI Estate (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
·	Date on which the threshold was crossed: February 20, 2026
---	---
·	Threshold that is crossed: 10%
·	Denominator: 43,662,403
·	Notified details:
A) Voting rights	Previous		After the transaction
---	---	---	---	---	---	---	---	---	---	---	---	---
	notification
	# of voting rights		# of voting rights				% of voting rights
			Linked to		Not linked to the		Linked to			Not linked to
Holders of voting<br> rights			securities		securities		securities			the securities
Robert Taub		2,712,510		2,712,510				6.21	%
BMI Estate		567,484		567,484				1.30	%
Robelga SRL		1,030,806		1,030,806				2.36	%
Subtotal		4,310,800		4,310,800				9.87	%
TOTAL				4,310,800		0		9.87	%		0.00	%
B) Equivalent financial instruments	After the transaction
---	---	---	---	---	---	---	---	---
				# of voting
				rights that may
****			****	be acquired if	****		****
	Type of financial			the instrument	% of voting		****
Holders of equivalent financial instruments	****	instrument ****	Expiration date ****	is exercised	****	rights	****	Settlement
Robert Taub		Warrants	08/06/2027	25,000		0.06	%	cash
Robert Taub		Warrants	14/06/2028	25,000		0.06	%	cash
TOTAL				50,000		0.11	%

^^

TOTAL (A & B)	#of voting rights	% of voting rights
	4,360,800	9.99	%
·	Full chain of controlled<br> undertakings through which the holding is effectively held: Robelga SRL is 100% owned<br> by BMI Estate (a partnership (société simple ) without legal personality).<br> Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of<br> BMI Estate.
---	---

*

* *

Contact:

---

Nyxoah

John Landry, CFO

IR@nyxoah.com

Attachment

·	2026 02 27 PR Transparency notification (Robert Taub) (ENG)

Exhibit 99.4

Publication relating to transparency notification

March 13, 2026

REGULATED INFORMATION

Publication relating to transparency notification

Mont-Saint-Guibert (Belgium), March 13, 2026,10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

BNP Paribas Asset Management

On March 11, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas

Asset Management Europe SAS holds 1,307,817 voting rights, representing 3.00% of the total number of voting rights on March 9, 2026 (43,662,403).

The notification dated March 11, 2026 contains the following information:

·	Reason for the notification:
·	Acquisition or disposal of voting securities or voting rights
---	---
·	Downward crossing of the lowest threshold
·	Notification by: a parent undertaking or a controlling person
---	---
·	Person subject to the notification requirement: BNP Paribas Asset Management SA (with address at SA 47000-75318 Paris cedex 09-France)
·	Date on which the threshold was crossed: March 9, 2026
·	Threshold that is crossed: 3%
·	Denominator: 43,662,403
·	Notified details:
A) Voting rights	Previous
---	---	---	---	---	---	---	---	---	---	---	---	---
	notification		After the transaction
	# of voting rights		# of voting rights				% of voting rights
			Linked to		Not linked to the		Linked to			Not linked to
Holders of voting rights			securities		securities		securities			the securities
BNP Paribas Asset		0		0				0.00	%
Management Holding
BNP Paribas Asset
Management Europe		1,409,791		1,307,817				3.00	%
SAS
Subtotal		1,409,791		1,307,817				3.00	%
TOTAL				1,307,817		0		3.00	%		0.00	%
·	Full chain of controlled<br> undertakings through which the holding is effectively held: The subsidiary BNP Paribas<br> Asset Management Europe SAS is controlled by the parent company BNP Paribas Asset Management<br> Holding. This parent company is itself controlled by the parent company BNP Paribas SA, which<br> benefits from an exemption from aggregating its shareholdings with those of its subsidiaries<br> investment companies, in accordance with article 21, paragraph 2 of the Royal Decree of February<br> 14, 2008 on the disclosure of major shareholdings.
---	---
·	Additional information:<br> The subsidiary BNP Paribas Asset Management Europe SAS is an investment company that exercises<br> voting rights on a discretionary basis in the absence of specific instructions.
---	---

*

* *

Contact:

Nyxoah

John Landry, CFO

IR@nyxoah.com

Attachment

·	2026 03 13 PR Transparency notification (BNP Paribas)<br>(ENG)